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ABSTRACT 
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Cancer is the second leading cause of death. As such, discovery and development 
of anticancer agents has attracted a great deal of attention by several pharmaceutical 
companies as well as non-profit organizations. Almost half of the approved anticancer 
agents are either natural products or semi-synthetic derivatives derived their off. Recently, 
phytochemical investigation of twigs of Clausena lansium has led the isolation of a new 
carbazole alkaloid, mafaicheenamine A (1). While exhibiting moderate activity against KB 
(1C50 = 7.68 μg/mL) and NCI-H187 (1C50 = 13.27 μg/mL), compound 1 showed potent 
activity against MCF7 (1C50 = 2.96 μg/mL). In this study, the synthesis of compound 1 
was successfully accomplished. In view of the importance and utility of fluorine 
substituents in drug discovery, the usefulness of our synthetic approach was extended 
towards the synthesis of 6-fluoromafaicheenamine A (2), an unnatural analogue of 1. On 
the other hand, bioassay-guided isolation from the broths of Streptomyces sp. IFM 10937 
has led to a new tyrosine derivative 3 which possess very promising trail-resistance-
overcoming activity. Consequently, the synthesis of compound 3 was also targeted and 
achieved successfully in the course of this study.  
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 ملخص الرسالة
 
 
 ياسر عباس        :الاسم الكامل
 
   ، غير طبيعيA enimaneehciafam-)±( مجموع خلاصات مضاد للأورام :عنوان الرسالة
  والتي تحدث بشكل طبيعي مشتق التيروزين-6  A nimaneehciafamoroulf
 
 كيمياء           التخصص:
 
 , 6102مايو :تاريخ الدرجة العلمية
السرطان هو السبب الرئيسي الثاني للوفاة. على هذا النحو، واكتشاف وتنمية العوامل المضادة للسرطان  
وقد اجتذب قدرا كبيرا من الاهتمام من قبل العديد من الشركات الدوائية وكذلك المنظمات غير الهادفة للربح. ما 
أو المشتقات شبه التركيبية المستمدة من يقرب من نصف العوامل المضادة للسرطان إما المنتجات الطبيعية 
أدى عزل  muisnal anesualCالطبيعة. في الآونة الأخيرة، حديثا ً التحقيق الكيميائي النباتي من اغصان 
. في حين أنه يظهر النشاط المعتدل ضد )1(A enimaneehciafam،  diolakla elozabracالجديد 
ميكروغرام / مل)، وأظهر مركب  72.31 = 05C1( 781H-ICNميكروغرام / مل) و 86.7 = 05CI( BK
ميكروغرام / مل). في هذه الدراسة، تم تحضير تركيب المركب  69.2 = 05CI( 7FCMالنشاط قوية ضد  1
بنجاح. ونظرا لأهمية وفائدة مستبدلات الفلور في اكتشاف العقاقير، تم تمديد فائدة الطبيعة الاصطناعية لدينا  1
. من ناحية أخرى،  من قبل  1، مشتقات غير طبيعي )2(A enimaneehciafamoroulf-6نحو تخليق 
التي  3. أدى إلى التيروزين جديد مشتق 73901 MFI .ps secymotpertSالأحيائي المساند من المرق 
تم استهدافة وتحقق  3. ونتيجة لذلك، تحضير مركب   LIARTتمتلك نشاط واعد جدا للتغلب والمقاومة على
 بنجاح في سياق هذه الدراسة أيضا.
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CHAPTER 1 
INTRODUCTION 
1.1  Cancer: 
Cancer, a genetically caused diseases, follows abnormality in cell growth and cell 
death pathways due to genomic alterations. The unrestrained cell growth that leads to 
accumulation of unwanted cells in the vicinity of normal cells eventually progresses to the 
form of tumor and then spreading to the different parts of a body (metastasis). Cancer still 
remains a huge torment worldwide since very limited advancement so far has been made 
to secure remedies for the treatment of this disease [1]. Recent reviews from the 
International Union Against Cancer and the American Cancer Society have disclosed that 
in the last year 12 million diagnosis of cancer occurrence have been reported whereas 7 
million mortality have been caused worldwide and these mortalities are estimated to 
increase twofold by 2030 [2]. Apoptosis, a process of programmed sequence that results in 
cell death, is a biochemical process that eliminates undesirable cells and regulate tissue 
homeostasis genetically. Surgery, chemotherapy and radiotherapy are the major 
approaches for the treatment of cancer [3]. 
The use of incorrect diet, the environment and genetic predisposition can be the 
factors resulting in cancer but prediction for cancer cannot be made on these factors alone. 
All cancers begin with mutations in DNA and gene changes within cells. However, the 
initial causes of mutation still remains a mystery which in turn leads to impair the discovery 
in cancer treatment [4].  The mutation resulting in cancers could take years to progress to 
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its detrimental phase. The mutations in DNA or altered gene regulation can normally be 
corrected by normal cells but failure in such correction leads to unrestrained cell growth 
and consequently invasion of normal and local cells, leading to cancer [5]. 
1.2  Apoptosis: 
Apoptosis is a process in which a cell follows a sequence on the way to death upon 
stimulation of a specific signal [6]. In the 1970’s Kerr et al., were the first to investigate 
and study apoptosis and since then it has been remained a significant part of scientific 
attention. Factors that activate apoptosis include p53, a tumor suppressor gene, and 
caspases, a cysteine protease family. Any mutation or alteration in p53 disrupt the 
functioning of the apoptotic process which in turn escalates tumor progression. The 
activated caspases enzymes are responsible for the degradation of nuclear DNA and 
breakdown of critical proteins, cytoskeleton and nuclear membrane. Any obstruction in the 
functioning of caspases causes hindering of the apoptosis process. The death receptor cells 
also play an important role in the regulation of apoptosis. Any malfunctioning or incorrect 
signaling to these death receptor cells can also leads to inhibition of apoptosis and, hence, 
to the progression of cancer [7]. 
The genomic alterations in cancers cause the deregulation of cell growth and cell 
death pathways, which eventually leads to the relentless cancer cell growth at the expense 
of cancer cell death. Therefore, targeting cancer growth pathways to develop therapeutics 
that could trigger apoptotic pathways is gaining increasing focus from the research 
community. Since apoptosis initiation is governed by both the mitochondria-involved 
intrinsic pathway and death receptors-mediated extrinsic pathway, the eventual target of 
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such therapies is to restore endogenous death pathways in order to drive cancer cells into 
self-destruction. Among the several cell death pathways, apoptosis is the best 
characterized. Hence, apoptosis plays an important role both in carcinogenesis and cancer 
treatment. Consequently, several therapeutic agents targeting apoptosis are currently in 
clinical trials [8].  
1.3 Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) 
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL), a tumor necrosis 
factor (TNF) family member [9, 10], selectively activates apoptotic pathways in cancer 
cells [11] by binding on the death receptors DR4 [12, 13] and DR5 (Figure 1) [14, 15]. 
After initiation by the death-receptor pathway, TRAIL-induced apoptosis results in 
activation of effector caspase-3, death-inducing signaling complex (DISC) formation and 
proteolytic activation of caspase-8 [16]. 
 
                                  
       
  
  
Figure 1 TRAIL receptor system 
 
 
4 
 
In addition, death receptors belong to the tumor necrosis factor receptor (TNFR) 
family that can engage intracellular apoptotic pathways.  
  
 
 
 
 
Figure 2  Trail and its receptors 
The two approaches that have been employed to target TRAIL apoptotic pathway 
are recombinant human TRAIL (rhTRAIL) ligands and its agonistic antibodies against 
DR4 and DR5. These TRAIL agonists are currently in phase I-II clinical trials and are 
expected to lead to the genesis of a new class of anticancer therapeutics targeting apoptotic 
pathways. However, many hurdles yet to be overcome until these TRAIL agonists can be 
developed into effective clinical cancer therapeutics [16]. 
TRAIL has emerged as an attractive antineoplastic agent due to its remarkable 
ability of killing selectively tumoral cells while leaving normal cells unscathed [17]. Unlike 
the other members of the TNF superfamily, in vivo administration of TRAIL has been 
proven to be safe [18]. However, in the case of highly malignant tumors, a reasonable 
numbers of cancer cells have intrinsic or acquired resistance to TRAIL-induced apoptosis 
[19]. Therefore, discovery of compounds that can abrogate TRAIL resistance has attracted 
a great deal of attention in anticancer drug discovery.  
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In a recent study, bioassay-guided fractionation of Streptomyces sp. IFM 10937, 
has led to the isolation of a new tyrosine derivative 3 (Figure 3) [12]. Compound 3 was 
evaluated for its activity in overcoming TRAIL resistance in AGS (human gastric 
adenocarcinoma) cells. Combined treatment of 75 or 150 μM of 3 and 100 ng/mL TRAIL 
with AGS cell lines reduced cell viability to 77 ± 7% and 67 ± 5% of control levels (p < 
0.01), respectively, which suggested a possible synergism between the two agents.  
 
Figure 3 Chemical structure of tyrosine derivative 3 
 
1.4  Natural products as anti-cancer agents 
Nature is a fascinating foundation of novel medicinal compounds with a remarkable 
chemical diversity, originating from millions of species of plants, animals, marine 
organisms and microorganisms as potent anti-cancer agent [20]. The first known remedy 
for malignant tumors from plant–derived natural products was the roots of the autumn 
crocus (Colchicum autumnale), described by the Greek physician Dioscorides in ca. 50 
A.D [21]. The alkaloid colchicine (37, Figure 4) was subsequently isolated from C. 
autumnale [22]. In the year 1958, elatericins A and B (38 and 39, Figure 5) were isolated 
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from Ecballium elaterium L. which showed strong activity against mouse sarcoma cells 
[23]. 
  
Figure 4 Colchicine, vinblastin and vincristine 
Soon after, the famous alkaloids vinblastine and vincristine (40 and 41, Figure 5) 
were discovered from Catharanthus roseus [24]. These antitumor alkaloids have shown 
activity against a variety of cancer types including lymphoma, leukemia, breast, and lung 
[25], and their semi-synthetic analogues are used as remedies for the treatment of breast 
and lung cancers as well as various leukemias [26]. 
 
Figure 5 Vinca alkaloids, vinblastin and vincristine. 
In the year 1937, the establishment of the National Cancer Institute (NCI) spurred 
a major resurgence in anti-cancer drug discovery. More than 500,000 compounds for 
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potential cytotoxic activity [19] have been screened by the NCI since the last 50 years [27]. 
Several natural products such as β-lapachone (42) [28], combretastatin A4PO4 (43) [29], 
and betulinic acid (44) [30] have been isolated and advanced to either preclinical or clinical 
trials (Figure 6). 
 
Figure 6 β-Lapachone, combretastatin A4PO4, and betulinic acid 
Taxol® (45, Figure 8) was isolated from the bark of the Pacific Yew in 1966 [31], 
which represent one of the most successful stories of plant-derived anti-cancer agent. 
Taxol® is being used against breast and colon cancers, refractory ovarian cancer and 
Kaposi’s sarcoma [32]. As a result of taxol’s success, docetaxel (Taxotere®) (46, Figure 
7) was prepared by Potier and coworkers and is used in the treatment ovarian, breast, and 
various lung cancers [33].   
 
Figure 7 Taxol and docetaxel. 
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Schweinfurthins is a family of unique natural products that displayed potent anti-
cancer activities in the NCI’s 60–cell line; for instance schweinfurthins A and B (47 and 
48, Figure 8) are potent and selective anti–proliferative agents. 
 
Figure 8 Schweinfurthins A and B. 
Etoposide (49, Figure 9) is an epipodophyllotoxin, derived from the mandrake plant 
Podophyllum peltatum and the wild chervil Podophyllum emodi. It has shown efficacy in 
testicular cancer when used in combination with bleomycin (also derived from a natural 
product) and cisplatin and have shown activity against small-cell lung carcinoma. 
Likewise, homoharringtonine (50, Figure 9), an alkaloid isolated from Cephalotaxus 
harringtonia (Cephalotaxacea) [30] has shown efficacy against various leukemia [34]. 
 
Figure 9 Etoposide and homoharringtonine 
Sorafenib (Nexavar, 51, Figure 10) is a formal de novo new chemical entity which 
has been approved by the FDA in years 2005 and 2007 for the treatments of renal cell 
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carcinoma and hepatocellular carcinoma, respectively. The second drug that probably came 
about from a de novo sourcing is ataluren (Translarna, 52, Figure 10), which was approved 
in the EU in the year 2014 for the treatment of patients with genetic disorders due to a 
“nonsense” mutation. However, the first anticancer drug constructed by use of fragment 
screening and model fitting, vemurafenib (Translarna, 53, Figure 10), was approved by the 
FDA in 2011 [35]. 
 
Figure 10 Sorafenib, ataluren and vemurafenib 
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CHAPTER 2 
LITERATURE REVIEW 
2.1  Literature review of Bioactive Carbazole Alkaloids 
Carbazole alkaloids show a range of pharmacological activities including anti-
cancer, anti-bacterial and anti-HIV activities [36, 37]. In addition, they possess effective 
cytotoxic activity against human leukemia cells, prostate cancer cell lines, viral and clinical 
pathogens [38-41]. 
Carbazomycin A and B, isolated from Streptoverticillium ehimense, inhibited the 
growth of phytopathogenic fungi and possess anti-yeast and antibacterial activities [42]. 
Carbazomycin G and H, isolated from the same plants, have become fierce synthetic targets 
because of their novel structures and their potent useful biological activities [43].
  
 
Figure 11 Structure of naturally occurring bio-active carbazole alkaloids. 
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Carbazole and their derivatives are strong antitumor agent. These derivatives 
exploit the activity DNA topoisomerase II resulting in inhibition of enzyme. These also 
interact with DNA in a manner resulting in covalent adducts that are facilitated by the 
oxidation with cytochromes P450 (CYP) and peroxidases [28].  
Murrayafoline A and murrayquinone A, exhibiting cytotoxic activities, were 
isolated from Murraya euchrestifolia (Figure 11). Whereas murrayquinone A possess 
appreciable cytotoxic activity against SK-MEL-5 and Colo-205 cells [44], murrayafoline 
A was found to induce apoptosis and inhibit cell cycle [45]. Ellipticine and its derivatives 
have shown substantial antitumor and anti-HIV activities. The high activity against 
numerous types of cancers and reduced toxicity towards normal cells have increased 
immense interest in ellipticine [46].  Murrayanine (Figure 12), a novel carbazole alkaloid, 
was isolated from Murraya koenigii [47]. Murrayanine possessed cytotoxicity against 
cultured KB cells. Ondansetron (Figure 12), a carbazolone based synthetic drug has shown 
potent 5-HT3 receptor antagonist activity. Ondansetron is used to decrease acute sickness 
often linked to chemotherapy and radiotherapy in cancer treatment [48]. Dimeric carbazole 
alkaloids, clausenamine A and chrestifoline A (Figure 12) were isolated from Clausena 
excavate and Murraya euchrestifolia and M. koenigii (Rutaceae), respectively. These 
compounds have demonstrated minimum cytotoxicity towards some lung cancer and 
melanoma cells as well as weak subpanel selectivity [49-51]. 
12 
 
 
Figure 12 Structure of a synthetic and naturally occurring dimeric carbazole alkaloids 
Itoa et al. isolated new carbazole from Murraya koenigii, exhibiting prominent 
cytotoxic activity against human leukemia cell line HL-60 cells. Mahanine, pyrayafoline-
D, and murrafoline-I, (Figure 13) were capable in inducing apoptosis in HL-60 cells.  The 
activity shown by these three alkaloids suggested they could be contenders for a cancer 
chemotherapeutic agent [52]. 
 
Figure 13 Chemical structure of carbazole alkaloids from Murraya koenigii. 
Clausine–TH and Clausine–K (Figure 14) were isolated from the stem bark of Clausena 
excavata. These alkaloids have shown potent cytotoxicity against the CEM-SS cell lines 
with IC50 value of 2.1 µg/mL and 5.1 µg/mL, respectively [53]. 
 
 
 
13 
 
Figure 14 Chemical structure of Clausine-TH and Clausine-K. 
Nakahara et al. has reported the isolation of an active alkaloid, (+)-mahanine 
(Figure 15) that exhibited a range of pharmacological activities such as antimutagenic 
towards heterocyclic amines such as Trp-P-1, cytotoxic activity against tumor cell line 
HL60 and antibacterial activity against Bacillus cereus and Staphylococcus aureus with 
MIC100 values of 6.25 and 12.5 µg/mL, respectively [54]. 
 
Figure 15 Carbazole extracted from Micromelum minutum. 
Ito et al. have isolated nine carbazole alkaloids (Figure 16) from Clausena anisata 
which have shown promising antitumor activities. The structure-activity relationship 
analysis on the existing antitumor carbazole alkaloids has suggested that ekeberginine 
might be valuable as antitumor promoters in chemical carcinogenesis [55]. 
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Figure 16 Nine isolated carbazole alkaloids from Clausena anisata. 
Du et al. have reported ten new carbazole alkaloids, claulansines (54-63) and seven 
known analogues (64-70 Figure 17) isolated from the stems of Clausena lansium. 
Pharmacological screening of these compounds have indicated that 54, 59, 61-63, 66, 67 
and 70 showed selective neuroprotective effects [56]. 
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Figure 17 Carbazole alkaloids isolated from the stems of Clausena lansium. 
Maneerat et al. have recently reported isolation and characterization of a new 
carbazole alkaloid named mafaicheenamine A 1 (Figure 19) from the twigs of Clausena 
lansium [51]. Compound 1 was screened for antitumor activity which revealed that 1 has 
potent activity (1C50 = 2.96 μg/mL) against breast cancer (MCF7) and moderate activities 
against oral cavity cancer (KB, 1C50 = 7.68 μg/mL), and small lung cancer (NCI-H187, 
1C50 = 13.27 μg/m1L). 
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       Figure 18 Mafaicheenamine A. 
 
2.2  Literature review of Carbazole Alkaloid synthesis 
The major syntheses endeavors of the alkaloids, particularly the older ones, are based 
on the well-known synthetic strategies those are based on the Fischer indole synthesis 
(Scheme l) or coupling of the two substituted benzene rings followed by cyclization 
(Scheme 2). The effectiveness of these synthetic methods is limited due to the lack of the 
regioselectivity and scarcity of different substituted cyclohexanones or benzenes coupling 
partners [57]. 
 
Scheme 1: Fischer Indole synthesis of carbazole 
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Scheme 2: Carbazole synthesis via Ullmann condensation 
The electrophilic aromatic substitution of functionally diverse electron-rich 
arylamines  72 with tricarbonyliron-coordinated cyclohexadienylium ions 71 followed by 
concomitant oxidative cyclization of the arylamine-substituted tricarbonyl(η4-
cyclohexadiene)iron complexes 73 opened up the way to highly convergent total syntheses 
of a broad range of biologically active carbazole alkaloids 74. Over the past decades 
different procedures for the ironmediated oxidative coupling of arylamines with a 
cyclohexadiene to carbazole derivatives (Scheme 3) have been developed [58]. 
 
Scheme 3: Iron mediated carbazole synthesis 
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The one pot transformation of the arylamine-substituted tricarbonyl(η4-
cyclohexadiene)iron complex 73 to the 9H-carbazole derivative 74 proceeds via a 
sequence of cyclization, aromatization, and demetalation. The cyclizing dehydrogenation 
leads to the intermediate tricarbonyliron-complexed 4a,9a-dihydro-9H-carbazole 75  and 
subsequent intramolecular, syn-stereospecific hydrogen transfer afforded compound 77 
[59].  
 
Scheme 4: Mechanism for Iron catalyzed carbazole synthesis 
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The dehydrogenation via the tricarbonyl(η5-cyclohexadienylium)iron derivatives 
78 and 79 provides the dihydrocarbazole 75. Further dehydrogenation affords the 
tricarbonyl(η6-arene)iron complex 80, which demetalates spontaneously to the carbazole 
derivative 74 (Scheme 4). This methodology has been widely used for the total synthesis 
of a broad range of 1-oxygenated, 3-oxygenated, and 3,4-dioxygenated carbazole 
alkaloids [60]. 
The electrophilic aromatic substitution of the electron-rich arylamines 83 by the 
molybdenum complexed cation 82 afforded regio- and stereoselectively the molybdenum 
complexes 84 which was subject to oxidative cyclization with concomitant aromatization 
and demetalation to produce the carbazole derivatives 85 (Scheme 5) [62]. 
 
Scheme 5: Molybdenum mediated carbazole synthesis 
The cyclodehydrogenation of diphenylamines to carbazole derivatives has been 
accomplished with palladium(II) acetate catalyst. Furukawa et al. reported the synthesis of 
murrayastine 89. Ullmann-Goldberg coupling of N-acetyl-2,3-dimethoxyaniline 86 and 2-
bromo-5-methylanisole 87 with Cu and K2CO3 in pyridine followed by hydrolysis provided 
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the diarylamine 88, which was subjected to cyclodehydrogenation with palladium(II) 
acetate to afford murrayastine 89 (Scheme 6) [63]. 
 
Scheme 6: Carazole synthesis via Ullmann-Goldberg coupling 
One of the most versatile approaches to highly functionalized carbazoles is the 
sequential palladium-catalyzed C–N/C–C coupling for assembly of the central pyrrole 
moiety. Many total syntheses of naturally occurring carbazole alkaloids are following this 
route. The initial C–N bond formation by Buchwald–Hartwig amination between aryl 
halides or triflates 90 with arylamines 92 afforded the diarylamines 93 (Scheme 7) which 
was then oxidative cyclized to the carbazoles 94 via a double C–H bond activation, using 
palladium(II) catalyst [64]. 
Scheme 7: Synthesis of carbazole 94 by Bucwald-Hartwig amination and subsequent     
oxidative cyclization of diarylamine 93 
The first total synthesis of the 1,6-dioxygenated carbazole alkaloids clausine G 103, 
clausine I 102, and clausine Z 104 was achieved  using  palladium catalyzed approach 
(Scheme 8) [65]. Buchwald–Hartwig coupling of the arylamine 95 with p-bromoanisole 96 
afforded the diarylamine 97 which in turn was subjected to oxidative cyclization to produce 
carbazole 98. Clausine G 103 is readily prepared by catalytic debenzylation of the central 
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intermediate 98. Reduction of ester function of 98 with lithium aluminum hydride gave 
compound 99. The removal of the benzyl protecting group then eventually led to the 
synthesis of clausenol 100. Likewise, reduction of intermediate 98 with DIBAL-H) and 
subsequent oxidation of the benzylic alcohol afforded the 3-formylcarbazole 101.  
 
Scheme 8: Palladium mediated catalytic synthesis of carbazole 
Construction of the carbazole framework involving the copper(II)-catalyzed 
arylamine arylation followed by palladium(II)-mediated oxidative cyclization has been 
reported by Menendez et al. (Scheme 9) [66]. The diarylamines 105, obtained by copper(II) 
acetate-catalyzed N-arylation of arylamines 91 with phenyllead triacetate 106 was 
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subjected to oxidative cyclization using palladium(II) acetate under microwave irradiation 
to afford the carbazoles 94.  
 
Scheme 9: Copper catalyzed carbazole synthesis 
  
This procedure was applied to the synthesis of murrayafoline A 109 [67]. The 
palladium(II)-catalyzed version with copper(II) acetate as co-oxidant, originally reported 
by Knolker et al. for the synthesis of murrayafoline A 109, was employed for the synthesis 
of 2-methoxy-3-methylcarbazole 107, and glycozolidine 108 (Scheme 10), as well as some 
non-natural carbazoles [68]. 
 
Scheme 10: Synthesis of natural carbazole using phenylleadtriacetate 
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CHAPTER 3 
RESULTS AND DISSCUSSIONS 
3.1  Synthesis of mafaicheenamine A 
 
Figure 19 Retosynthetic analysis for mafaicheenamine A. 
The synthesis of compound 1 was envisioned from intermediate 11 which was to 
be transformed to 1 by the operations of olefin metathesis followed by oxidative cyclization 
(Figure 20). To this end, ester 5 was reacted with allyl bromide in DMF, using K2CO3 as a 
base, to produce the known ester 6 [69]. The Claisen rearrangement of 6 to the 
corresponding C-allyl phenol in ortho-dichlorobenzene, N,N-dimethylaniline or DMF 
either by conventional heating or under microwaves was very low yielding (32%), 
requiring prolonged heating and higher reaction temperature (˃ 150 oC). In all the attempts, 
the reaction had led to the recovery of either hydrolyzed acid (in case of N,N-
dimethylaniline) or starting material (in case of ortho-dichlorobenzene and DMF). 
Consequently, the nitro group of 6 was reduced with iron powder in a mixture of ethanol, 
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acetic acid and water promoted by ultrasonic irradiation, to generate 7 in high yield (90%) 
[70]. The initial attempts of Claisen rearrangement of 7 in N,N-dimethylaniline under 
conventional heating or microwave irradiation were very sluggish, resulting the formation 
of only 10% of the desired product. However, with an optimized condition the reaction in 
DMF under microwave irradiation at 180 oC for 2 h gave the desired rearranged phenol 8 
in high yield (85%). The chemoselective methylation on the phenolic OH of 8 with 
diazomethane in diethyl ether did not go to the completion even with the use excess of 
diazomethane; the desired 9 was formed in a low yield (15%) along with the recovery of 
8. In a second attempt, methylation was realized by stirring the solution of 8 in DMF with 
1.3 equivalent of K2CO3 for 30 min before adding 1.2 equivalent of iodomethane (Scheme 
11). The amount of K2CO3 and short reaction time (1.5 h) was critical to obtain the desired 
9 in high yield (76%). The N-arylation of ester 9 with bromobenzene under Buchwald-
Hartwig conditions (Pd(dba)2, BINAP) rendered the desired 10 in a very low yield (16%). 
The reaction become relatively cleaner when the combination of Pd(OAc)2 and JohnPhos 
were used as catalyst and ligand, respectively. However, column chromatography 
purifications in this case turned out to be tedious and the desired 8 was obtained in low 
(20%) yield. Consequently, N-arylation of ester 9 was realized under Barton conditions 
[71], using phenylead triacetate and copper(II) acetate as a catalyst to furnish the desired 
10 in good yield (66%). Cyclodehydrogenation of 10 in acetic acid or DMF with catalytic 
or stoichiometric amounts of palladium(II) acetate and copper(II) acetate using either 
thermal induction [72] or microwave heating [73] at elevated temperatures did not yield 
the desired 11, the decomposition of 10 was observed in all cases (Scheme 12).  
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Scheme 11: Synthesis of intermediate 9 
Failure in cyclodehydrogenation of 10 led us revised our synthetic strategy as 
outlined in scheme 12. N-arylation of ester 13 with phenylead triacetate under Barton 
conditions furnished the desired 14 in good yield (67%). The key step of 
cyclodehydrogenation on 14 was performed in acetic acid at 100 oC, using palladium(II) 
acetate as a catalyst to furnish the desired 16 in good yield (60%). Removal of O-benzyl 
protection of 16 with catalytic hydrogenation produced 18 (clausine E) in 34% overall yield 
from 13. Despite the fact that six procedures for the synthesis of clausine E are known [74], 
our synthetic method provide an efficient access to the synthesis of clausine E in an overall 
high yielding reaction sequence. Next, 18 was reacted with allyl bromide in DMF, using 
K2CO3 as a base, to produce 20 which in turn was subjected to Claisen rearrangement under 
the optimized condition in DMF, using microwave irradiation at 180 oC for 2 h to afford 
the desired C-prenylated phenol 22 in 82% yield. The chemoselective methylation on the 
phenolic OH of 22 was realized with iodomethane in DMF to achieve 24 (Scheme 2). 
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Olefin cross-metathesis reaction between intermediate 24 and 2-methyl-2-butene, using 
second-generation Grubbs catalyst yielded the desired 26 in excellent yield (91%). With 
compound 26 in hand, we next moved towards the construction of the dihydroisocoumarin 
unit of 1.  
To this end, acid 28 was treated with m-CPBA in CH2Cl2 followed by work-up with 
saturated NaHCO3 readily generated the desired 1 in 78% yield (Scheme 2). All the spectral 
data of 1 matched with those of natural mafaicheenamine A [51]. 
Substitution of aromatic and heteroaromatic rings with fluorine substituent is a 
common practice in drug discovery. The incorporation of fluorine into a molecule can 
improve drug potency [75], target selectivity [76] and also can address issues associated 
with drug metabolism [77]. In a previous study, the effect of aromatic fluorine substitution 
in a series of thrombin inhibitors was investigated. The study revealed that incorporation 
of fluorine at C-4 of phenyl ring significantly enhanced the activity compared to when it 
was introduced at other positions of the phenyl ring.  The high potency of 4-fluorophenyl 
derivative was rationalized due to the dipolar C–F…H–C and C–F…C=O interactions 
between the 4-fluorophenyl ring and the enzyme’s active site [78].   
Consequently, the usefulness of our synthetic approach was extended towards the 
synthesis of 6-fluoromafaicheenamine A (2), an unnatural analogue of 1. As depicted in 
Scheme 12, 6-fluoroclausine E 19 was synthesized from 13 by the reaction sequence of N-
arylation with 4-fluorophenylead triacetate, palladium(II) acetate mediated 
cyclodehydrogenation and removal of benzyl protection with catalytic hydrogenation. 
Likewise intermediate 27 was originated from 19 by the operations of Pd-catalyzed 
27 
 
allylation, Claisen rearrangement and O-methylation. Finally basic hydrolysis of ester 
function of 27 followed by oxidative cyclization furnished the desired 2 (Scheme 13). 
 
Scheme 12: Synthesis of mafaicheenamine A (1) and 6-fluoromafaicheenamine A (2) 
3.2 Synthesis of Tyrosine Derivative 
 Synthesis of the desired compound 3 was envisaged from the olefin cross-metathesis 
reaction of intermediate 32, which in turn, was to be synthesized from Claisen 
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rearrangement of intermediate 31. Thus, L-tyrosine 30 was converted to intermediate 31 
by the operations of esterification, N-boc protection and O-allylation based on literature 
known procedures [79] (Scheme 13).   
However, Claisen rearrangement of intermediate 31 either under thermal or microwave 
irradiation conditions at different temperatures, using N,N-dimethylaniline or DMF as 
solvents were unsuccessful. For instance, under thermal conditions reaction in N,N-
dimethylaniline or DMF at reflux resulted the starting material intact whereas heating neat 
31 at elevated temperatures led to the decomposition of 31, with no desired product 
formation.  
Likewise, under microwave conditions, reaction at lower temperature (200 oC, 250 W, 
1 h) in DMF resulted unchanged 31 whereas heating the reaction at higher temperature 
(250 oC, 250 W, 45 minutes) in N,N-dimethylaniline had led to the deprotection of N-Boc 
group. Deprotection of N-Boc group under microwave conditions using mild base or under 
thermolytic conditions are well known [80]. To address the N-deprotection problem we 
moved on to make the N-acetyl derivative 33 which in turn was synthesized from 
intermediate 30 according to a literature known procedure [81] (Scheme 13). Claisen 
rearrangement of intermediate 33 in N,N-dimethylaniline under microwave irradiation at 
250 oC gave the desired rearranged phenol 34 in excellent yield (75%). Acetylation of 
intermediate 34 under standard conditions rendered 35 in a very high yield. Olefin cross-
metathesis reaction between intermediate 35 and 2-methyl-2-butene, using second-
generation Grubbs catalyst yielded the desired 36 in excellent yield (84%).  
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Scheme 13: Synthesis of Tyrosine derivative (3) 
 
It is noteworthy that O-prenylation of O-deallylated 33 followed by Claisen 
rearrangement would possibly have given access to the O-deacetylated 36. Finally, 
exposure of intermediate 36 under basic condition at room temperature ultimately produced 
the desired 3 in 43% overall yield from 33 (Scheme 13). All the spectral data of 3 matched 
with those of the previously isolated material [12].  
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CHAPTER 4  
EXPERIMENTAL 
 
4.1   Material and Method   
Pyrex glassware was used for the experimental needs. All glassware was washed and 
dried before use. For air and moisture sensitive reaction the glassware was washed and 
dried in an oven before initial use. Thin layer chromatography was systematically 
employed for the qualitative monitoring of the reactions performed and was frequently 
utilized while performing flash chromatography for the purification of the compounds 
synthesized. TLC analyses were executed on silica gel 60 F254 plates (E. Merck) and 
viewed under a UV lamp. Silica gel 100 from Fluka 44 Chemie AG (Buchs, Switzerland) 
was used for the packing of column. Chemicals were purchased from commercial sources, 
and they were used without any further purification unless otherwise specified. An inert 
atmosphere was used for reactions where necessary. Melting Points were determined on a 
Büchi apparatus (Büchi Labortechnik AG, Switzerland) and are uncorrected. Elemental 
analysis was carried out on a Perkin Elmer Elemental Analyzer Series 11 Model 2400 
(PerkinElmer Inc. USA). IR spectra were recorded on a NicoletTM 6700 FTIR 
spectrophotometer and were reported in wave numbers (cm-1). 1H and 13C NMR spectra 
were measured in CDCl3, CD3OD and d6-DMSO using TMS as internal standard on a 
JEOL JNM-LA 500 MHz spectrometer (JEOL USA Inc.). Multiplicities were reported as 
singlet (s), doublet (d), triplet (t), quartet (q) or multiplet (m), and coupling constants (J) 
were reported in hertz (Hz).  
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4.2 Synthesis of methyl 3-hydroxy-4-nitrobenzoate (5) 
 
3-hydroxy-4-nitrobenzoic acid 4 (5g) was suspended in MeOH (50 mL) and stirred at 0ºC 
for 15 minutes followed by the addition of SOCl2 (10 mL) drop-wise. The reaction was 
stirred overnight at room temperature and then evaporated under reduced pressure to get 
the title compound 5 as a yellow solid in quantitative yield. m.p. 83-85 oC; IR (neat) 3306, 
2959, 2920, 2850, 1722, 1621, 1586, 1521, 1474, 1434, 1323, 1282, 1223, 1145, 1098, 
1065 cm-1; 1 H-NMR (500 MHz; CDCl3): δ 3.97 (s, 3H), 7.61 (dd, J = 8.8, 1.5 Hz, 1H), 
7.84 (d, J = 1.4 Hz, 1H), 8.17 (d, J = 8.8 Hz, 1H), 10.5 (s, 1H); 13C-NMR (125.7 MHz, 
CDCl3): δ 52.90, 120.58, 121.66, 125.25, 135.79, 137.98, 154.66, 164.81. 
4.3 Synthesis of methyl 4-nitro-3-(prop-2-en-1-yloxy)benzoate (6) 
 
To a solution of 5 (5 g, 25.36 mmol) in DMF (50) was added anhydrous K2CO3 (4.21 g, 
30.43 mmol) followed by the addition of allyl bromide (2.57 mL, 30.43 mmol) e and the 
mixture was stirred overnight at room temperature. After consumption of starting material 
(TLC analysis), the reaction was quenched with water (50 mL) followed by the extraction 
with ethyl acetate (4 x 100 mL). The collective organic layers dried using Na2SO4 and 
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solvent removed using rotary evaporator to yield the title compound 6 as a pale yellow 
solid. Yield: 5.6 g, 93%: IR (neat) 3121, 2999, 2954, 1609, 1582, 1555, 1516, 1433, 1340, 
1009, 981 cm-1; 1H-NMR (500 MHz, CDCl3): δ 3.96 (s, 3H), δ 4.74-4.75 (d, J = 5.5 Hz, 
2H), δ 5.34-5.37 (d, J = 10.6 Hz, 1H), δ 5.48-5.52 (dd, J = 18.6 Hz, 1H), δ 6.01-6.07 (m, 
1H), δ 7.68-7.70 (dd, J = 1.8, 8.5 Hz, 1H), δ 7.74 (s, 1H), 7.82-7.33 (d, J = 8.2 Hz, 1H); 
13C-NMR (100 MHz, CDCl3): δ 52.84, 70.24, 115.92, 118.81, 121.57, 125.35, 131.35, 
134.75, 142.73, 151.40, 165.20. 
4.4 Synthesis of Methyl 3-(allyloxy)-4-aminobenzoate (7) 
 
To a suspension of 6 (0.3 g, 1.3 mmol) in a mixture of glacial acetic acid (4 mL), 
ethanol (4 mL) and water (2 mL) was added reduced iron powder (0.37 g, 6.6 mmol). The 
resulting suspension was exposed to ultrasonic irradiation at 30 °C for 3 h and the mixture 
was filtered to remove the iron residue, which was washed with ethyl acetate (30 mL). The 
filtrate was added 2M KOH (20 mL) and extracted with ethyl acetate (3 x 30 mL). The 
combined organic extracts were washed with brine (2 x 30 mL) and water (3 x 50 mL), 
dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude residue 
was resolved on silica column, eluting with hexanes-ethyl acetate (80:20) to afford the title 
compound 7 as a bright yellow oil. Yield: 0.25 g, 90%; IR (neat): 3373, 3312, 3025, 2946, 
1682, 1608, 1573, 1571, 1426, 1363, 1302, 1208, 1136, 1101 cm-1; 1H-NMR (500 MHz, 
CDCl3): δ 3.85 (s 3H, OCH3), 4.28 (br. s, 2H, NH2), 4.60 (d, J = 5.5 Hz, 2H, 
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OCH2CH=CH2), 5.30 (dd, J = 1.5, 10.3 Hz, 1H, OCH2CH=CH2), 5.41 (dd, J = 1.5, 17.1 
Hz, 1H, OCH2CH=CH2), 6.07 (m, 1H, OCH2CH=CH2), 6.67 (d, J = 8.2 Hz, 1H, H-5), 7.45 
(d, J = 1.8 Hz, 1H, H-2), 7.54 (dd, J = 1.7, 8.2 Hz, 1H, H-6); 13C-NMR (125.7 MHz, 
CDCl3): δ 51.66 (OCH3), 69.23 (OCH2CH=CH2), 112.59, 113.27, 117.86, 119.39, 124.21, 
132.98, 141.32, 144.95, 167.22 (C=O). Anal. Calcd for C11H13NO3: C, 63.76; H, 6.32; N, 
6.76%. Found: C, 63.72; H, 6.35; N, 6.71. 
4.5 Synthesis of Methyl 2-allyl-4-amino-3-hydroxybenzoate (8) 
 
In a microwave reaction vessel, through a solution of 7 (2.0 g, 9.7 mmol) in DMF 
(4 ml) was  bubbled nitrogen for 1 min and vessel was then placed inside CEM Discover 
S-Class microwave synthesizer where it was exposed to microwaves at 180 oC (260 W) for 
2 h. After completion of the reaction, the mixture was diluted with ethyl acetate (50 mL), 
washed with water (10 mL) and then washed with brine (5 x 10 mL), dried over anhydrous 
Na2SO4, filtered and concentrated under vacuum. Column chromatography purifications 
of the yellow oily material, eluting with hexanes-ethyl acetate (50:50) afforded compound 
8 as an off white solid. Yield: 1.7 g, 85%; m.p. 91-92 oC; IR (neat): 3408, 3313, 3002, 
2947, 1693, 1601, 1493, 1441, 1277, 1191, 1100, 1015 cm-1; 1H-NMR (500 MHz, CDCl3): 
δ 3.82 (s, 3H, OCH3), 3.89 (d, J = 6.1 Hz, 2H, ArCH2CH=CH2), 4.12 (br. s, 2H, NH2), 
5.15-5.19 (m, 2H, OCH2CH=CH2), 6.06 (m, 1H, OCH2CH=CH2), 6.60 (d, J = 8.2 Hz, 1H, 
H-5), 7.50 (d, J = 8.2 Hz, 1H, H-6); 13C-NMR (125.7 MHz, CDCl3): δ 31.64 
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(ArCH2CH=CH2), 51.57 (OCH3), 112.44, 116.13, 119.13, 125.49, 126.88 136.45, 139.87, 
142.00, 167.82 (C=O). Anal. Calcd for C11H13NO3: C, 63.76; H, 6.32; N, 6.76%. Found: 
C, 63.71; H, 6.34; N, 6.72. 
4.6 Synthesis of Methyl 2-allyl-4-amino-3-methoxybenzoate (9) 
 
In a solution of 8 (0.2 g, 0.97 mmol) in DMF (5 mL) was added K2CO3 (0.27 g, 
1.93 mmol) and after being stirred for 30 minutes at room temperature, iodomethane (0.1 
mL, 1.45 mmol) was added and the reaction mixture was further stirred for 1 h at room 
temperature. The mixture was diluted with water (30 mL) and then extracted with ethyl 
ether (2 x 15 mL). The combined organic layers was washed with water (10 mL) and brine 
(10 mL) and then dried over anhydrous Na2SO4 and evaporated under reduced pressure. 
Column chromatography of the light yellow oily material on silica gel eluting with 
petroleum ether-ethyl acetate (9:1) gave the title compound 9 as a dark pink crystalline 
solid. Yield: 0.16 g, 76%; m.p. 89-90 oC; IR (neat): 3505, 3374, 3026, 2938, 1687, 1612, 
1427, 1335, 1261, 1029 cm-1; 1H-NMR (500 MHz, CDCl3): δ 3.75 (s, 3H, OCH3), 3.83 (s, 
3H, OCH3), 3.85 (d, J = 5.8 Hz, 2H, ArCH2CH=CH2), 4.95-5.00 (m, 2H, ArCH2CH=CH2), 
6.05 (m, 1H, ArCH2CH=CH2), 6.62 (d, J = 8.2 Hz, 1H, H-5), 7.64 (d, J = 8.2 Hz, 1H, H-
6); 13C-NMR (125.7 MHz, CDCl3): δ 30.73 (ArCH2CH=CH2), 51.47 (OCH3), 59.92 
(OCH3), 112.59, 114.52, 119.49, 128.60, 135.98 137.88, 143.89, 145.10, 167.42 (C=O). 
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Anal. Calcd for C12H15NO3: C, 65.14; H, 6.83; N, 6.33%. Found: C, 65.10; H, 6.86; N, 
6.28. 
 
4.7 Synthesis of Methyl 2-allyl-3-methoxy-4-(phenylamino)benzoate (10) 
 
To a solution of compound 9 (0.25 g, 1.12 mmol) in dry CH2Cl2 (15 mL) was added 
phenyllead triacetate (0.67 g, 1.47 mmol) followed by the addition of copper(II) acetate 
(0.04 g, 0.22 mmol) and the reaction was stirred at room temperature for 24 h until the 
reaction was completed (TLC analysis). The mixture was filtered through a pad of celite 
and the filtrate was concentrated under reduced pressure. The residues was resolved on 
silica column, eluting with petroleum ether-ethyl acetate (9:1) to get the title compound 10 
as a pale yellow oil. Yield: 0.22 g, 66%; IR (neat): 3345, 3075, 2996, 1707, 1588, 1497, 
1430, 1254, 1135, 1036 cm-1; 1H-NMR (500 MHz, CDCl3): δ 3.82 (s, 3H, OCH3), 3.86 (s, 
3H, OCH3), 3.91 (d, J = 5.6 Hz, 2H, ArCH2CH=CH2), 5.00-5.04 (m, 2H, ArCH2CH=CH2), 
6.07 (m, 1H, ArCH2CH=CH2), 6.47 (br. s, 1H, NH), 7.09 (t, J = 5.6 Hz, 1H, Ar-H), 7.14 
(d, J = 8.6 Hz, 1H, Ar-H), 7.22 (d, J = 8.4 Hz, 2H, Ar-H), 7.36 (m, 2H, Ar-H), 7.68 (d, J = 
8.6 Hz, 1H, Ar-H); 13C-NMR (125.7 MHz, CDCl3): δ 30.90 (ArCH2CH=CH2), 51.54 
(OCH3), 60.65 (OCH3), 110.70, 114.67, 120.54, 120.64, 122.99, 126.04, 128.33, 128.39, 
129.46, 135.72, 137.78, 140.71, 141.06, 146.21, 167.32 (C=O). Anal. Calcd for 
C18H19NO3: C, 72.71; H, 6.44; N, 4.71%. Found: C, 72.66; H, 6.49; N, 4.65. 
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4.8 Synthesis of methyl 3-(benzyloxy)-4-nitrobenzoate (12) 
 
Potassium carbonate (0.9 g, 6.59 mmol) and benzylbromide (0.8 mL, 6.59 mmol) were 
sequencially added to a solution of methyl 3-hydroxy-4-nitrobenzoate (5) (1.0 g, 5.07 
mmol) in acetone (31 mL). The suspension was heated under reflux for 6 h and then water 
was added. The aqueous layer was extracted with ethyl acetate (15 mL x 4). The combined 
organic layers were washed with brine (10 mL x 2), dried over Na2SO4 and evaporated 
under vacuum. Purification of the residue by flash chromatography on silica gel (petroleum 
ether-ethyl acetate, 4:1) afforded compound 12 as light yellow crystals, in quantitative 
yield. m.p. 92-94 oC; IR (neat) 3116, 3085, 3059, 3035, 2960 , 2879, 2837, 1727, 1602, 
1524, 1495, 1437, 1421, 1374, 1372, 1294, 1266, 1232, 1213, 1188, 1113, 1080 cm-1; 1H-
NMR (500 MHz, CDCl3): δ 3.97 (s, 3H), 5.29 (s, 2H), 7.35 (t, J = 7.3 Hz, 1H), 7.40 (t, J = 
7.3 Hz, 2H), 7.47 (d, J = 7.4 Hz, 2H), 7.71 (dd, J = 8.2, 1.4 Hz, 1H), 7.84 (d, J = 1.4 Hz, 
1H), 7.84 Hz (d, J = 8.2 Hz, 1H); 13C-NMR (125.7 MHz, CDCl3): δ 52.85, 71.41, 116.10, 
121.72, 125.38, 127.18, 128.44, 128.77, 134.80, 135.04, 142.88, 151.44, 165.17.  
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4.9 Synthesis of methyl 4-amino-3-(benzyloxy)benzoate (13) 
 
To a suspension of 12 (0.3 g, 1.26 mmol) in a mixture of glacial acetic acid (3 mL), ethanol 
(3 mL) and water (1.5 mL) was added reduced iron powder (0.36 g, 6.57 mmol). The 
resulting suspension was exposed to ultrasonic irradiation for 3 h at 30 °C with TLC 
analysis monitoring for the completion of the reaction. The reaction mixture was filtered 
to remove the iron residue which was washed with ethyl acetate (30 mL). The filtrate was 
partitioned with 2M KOH and the basic layer was further extracted with ethyl acetate (3 x 
30 mL). The combined organic extracts were washed with brine (2 x 30 mL) and water (3 
x 50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The 
crude residue was then subjected to flash silica gel column chromatography (20% ethyl 
acetate in hexanes) yielding 13 (0.235g, 90%) as colorless crystalline solid, yield: 1.21 g 
(100%), m.p. 98-99 oC; IR (neat) 3493, 3387, 3005, 2945, 2872, 1693, 1605, 1515, 1452, 
1428, 1384, 1361, 1295, 1259, 1208, 1136, 1101, 1007 cm-1; 1H-NMR (500 MHz, CDCl3): 
δ 3.88 (s, 3H), 4.39 (br s, 2H), 5.08 (s, 2H), 6.69 (d, J = 7.9 Hz, 1H), 7.36 (t, J = 6.7Hz, 
1H), 7.41 (t, J = 7.0 Hz, 2H), 7.45 (d, J = 6.7  Hz, 2H), 7.61 (d, J = 1H), 7.61 (d, J = 8.2, 
Hz, 1H); 13C-NMR (125.7 MHz, CDCl3): δ 51.63, 70.38, 112.55, 113.21, 119.04, 124.40, 
127.76, 128.13, 128.55, 136.61, 141.64, 145.14, 167.28.  
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4.10 Synthesis of Methyl 3-(benzyloxy)-4-(phenylamino)benzoate (14) 
 
Following the same procedure adopted for the synthesis of 10, the reaction of 
compound 13 with phenyllead triacetate gave the title compound 14 as colorless crystalline 
solid. Yield: 0.26 g, 67%; m.p. 119-120 oC; IR (neat): 3399, 3024, 2946, 1692, 1587, 1515, 
1493, 1440, 1418, 1380, 1347, 1268, 1221, 1101 cm-1; 1H-NMR (500 MHz, CDCl3): δ 3.90 
(s, 3H, OCH3), 5.19 (s, 2H, OCH2Ph), 6.56 (br. s, 1H, NH), 7.08 (t, J = 7.3 Hz, 1H, Ar-H), 
7.21-7.24 (m, 3H, Ar-H), 7.33-7.36 (m, 2H, Ar-H), 7.39 (m, 1H, Ar-H), 7.42-7.45 (m, 2H, 
Ar-H), 7.48 (d, J = 7.0 Hz, 1H, Ar-H), 7.62 (dd, J = 1.8, 8.2 Hz, 1H, Ar-H), 7.65 (d, J = 
1.6 Hz, 1H, Ar-H); 13C-NMR (125.7 MHz, CDCl3): δ 51.81 (OCH3), 70.90 (OCH2Ph), 
111.02, 112.46, 115.35, 119.85, 120.36, 121.14, 123.19, 124.19, 127.96, 128.37, 128.71, 
129.41. 129.57, 136.34, 138.64 140.53, 145.68, 156.03, 167.18 (C=O). Anal. Calcd for 
C21H19NO3: C, 75.66; H, 5.74; N, 4.20%. Found: C, 75.61; H, 5.78; N, 4.15. 
4.11 Synthesis of Methyl 3-(benzyloxy)-4-((4 fluorophenyl)amino)benzoate (15) 
 
Following the same procedure adopted for the synthesis of 10, the reaction of 
compound 13 with 4-fluorophenyllead triacetate gave the title compound 15 as a brown 
thick oil. Yield: 0.29 g, 70%; IR (neat): 3408, 3033, 2947, 1890, 1706, 1593, 1559, 1525, 
1501, 1432, 1351, 1268, 1204, 1155, 1124, 1097 cm-1; 1H-NMR (500 MHz, CDCl3): δ 3.88 
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(s, 3H, OCH3), 5.17 (s, 2H, OCH2Ph), 6.44 (br. s, 1H, NH), 7.01-7.05 (m, 3H, Ar-H), 7.11-
7.17 (m, 2H, Ar-H), 7.38-7.49 (m, 5H, Ar-H),  7.42 (t, J = 7.3 Hz, 2H), 7.62 (dd, J = 1.8, 
8.2 Hz, 1H, Ar-H), 7.65 (d, J = 1.6 Hz, 1H, Ar-H); 13C-NMR (125.7 MHz, CDCl3): δ 51.79 
(OCH3), 70.89 (OCH2Ph), 110.38, 112.38, 116.02, 116.21, 119.73, 123.86, 124.24, 128.03, 
128.41, 128.72, 136.29, 136.40 139.27, 145.41, 159.19 (d, J = 243.0 Hz, C-6), 167.11 
(C=O). Anal. Calcd for C21H18FNO3: C, 71.78; H, 5.16; N, 3.99%. Found: C, 71.73; H, 
5.19; N, 3.93. 
4.12 Synthesis of methyl 1-(benzyloxy)-9H-carbazole-3-carboxylate (16) 
 
Under nitrogen atmosphere, to a solution of 14 (0.95 g, 2.85 mmol) in glacial acetic 
acid (60 mL) was added palladium(II) acetate (1.3 g, 5.7 mmol) and the mixture was heated 
at 100 oC for 24 h. The solvent was removed under reduced pressure and the residue was 
purified by flash chromatography on silica gel, eluting with petroleum ether-ethyl acetate 
(80:20) to afford 16 as a colorless crystalline solid. Yield: 0.5 g, 55%; m.p. 149-150 oC; IR 
(neat): 3358, 3032, 2946, 1678, 1629, 1583, 1495, 1406, 1344, 1309, 1230, 1149, 1092 cm-
1; 1H-NMR (500 MHz, CDCl3): δ 3.99 (s, 3H, OCH3), 5.31 (s, 2H, OCH2Ph), 7.27 (m, 1H, 
Ar-H), 7.39 (d, J = 7.3 Hz, 1H, Ar-H), 7.42-7.47 (m, 4H, Ar-H), 7.53 (d, J = 7.3 Hz, 2H, 
Ar-H), 7.72 (d, J = 1.6 Hz, 1H, Ar-H), 8.11 (d, J = 7.9 Hz, 1H, Ar-H), 8.51 (d, J = 1.6 Hz, 
1H, Ar-H), 8.53 (br. s, 1H, NH); 13C-NMR (125.7 MHz, CDCl3): δ 52.06 (OCH3), 70.71 
(OCH2Ph), 107.86, 111.23, 116.48, 120.30, 120.77, 121.89, 123.75, 123.79, 126.41, 
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128.16, 128.44, 128.72, 136.44, 139.53, 144.29, 167.92 (C=O). Anal. Calcd for 
C21H17NO3: C, 76.12; H, 5.17; N, 4.23%. Found: C, 76.08; H, 5.21; N, 4.17. 
4.13 Synthesis of Methyl 1-(benzyloxy)-6-fluoro-9H-carbazole-3-carboxylate 
(17) 
 
Following the same procedure adopted for the synthesis of 16, the 
cyclodehydrogenation of compound 15 in acetic acid gave the title compound 17 as a 
colorless solid. Yield: 0.09 g, 59%; m.p. 172-176 oC; IR (neat): 3325, 2939, 1687, 1608, 
1582, 1480, 1455, 1433, 1407, 1325, 1300, 1275, 1249, 1167, 1095, 1017 cm-1; 1H-NMR 
(500 MHz, CDCl3): δ 3.97 (s, 3H, OCH3), 5.27 (s, 2H, OCH2Ph), 7.17 (td, J = 2.4, 9.1 Hz, 
1H), 7.35-7.45 (m, 4H, Ar-H), 7.51 (d, J = 7.0 Hz, 2H, Ar-H), 7.69 (d, J = 1.3, 1H, Ar-H), 
7.72 (dd, J = 8.2, 1.6 Hz, 1H, Ar-H), 8.42 (d, J = 1.2, 1H, Ar-H), 8.51 (br. s, 1H, NH); 13C-
NMR (125.7 MHz, CDCl3): δ 52.11 (OCH3), 70.69 (OCH2Ph), 106.31, 106.50, 108.04, 
111.81, 111.90, 114.23, 114.44, 116.58, 121.89, 123.39, 124.34, 128.16, 128.47, 128.73, 
134.08, 135.78, 136.28, 144.36, 159.42 (d, J = 249.0 Hz, C-6), 167.76 (C=O). Anal. Calcd 
for C21H16FNO3: C, 72.20; H, 4.62; N, 4.01%. Found: C, 72.17; H, 4.65; N, 3.96. 
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4.14 Synthesis of Methyl 1-hydroxy-9H-carbazole-3-carboxylate (18) 
 
 To a suspension of 16 (0.48 g, 1.44 mmol) in a mixture of THF (20 mL) and ethanol (20 
mL) was added palladium on activated carbon (0.05 g, 10% wet basis) and the reaction 
mixture was subjected to hydrogenation in a Parr apparatus at 50 psi for 5 h. The mixture 
was filtered through a pad of celite, and the filtrate was concentrated under vacuum and 
loaded on a silica column, eluting petroleum ether-ethyl acetate (2:1) afforded 15 as a white 
solid. Yield:  0.32 g, 91%. The spectral data of 18 matched with those of earlier values 
[23]. 
4.15 Synthesis of Methyl 6-fluoro-1-hydroxy-9H-carbazole-3-carboxylate (19) 
 
Following the same procedure adopted for the synthesis of 18, the title compound 
19 was obtained as a white solid from the O-debenzylation of 17. Yield: 0.2 g, 95%; m.p. 
220-221; IR (neat): 3388, 3078, 2952, 1711, 1664, 1634, 1496, 1292, 1252, 1169 cm-1; 1H-
NMR (500 MHz, DMSO-d6): δ 3.91 (s, 3H, OCH3), 7.31 (td, J = 1.6, 8.8 Hz, 1H, Ar-H), 
7.52 (d, J = 1.3 Hz, 1H, Ar-H), 7.55 (dd, J = 4.2, 8.8 Hz, 1H, Ar-H), 8.10 (d, J = 7.9 Hz, 
1H, Ar-H), 8.38 (d, J = 1.3 Hz, 1H, Ar-H), 10.35 (br. s, 1H, NH), 11.64 (s, 1H, OH); 13C-
NMR (125.7 MHz, DMSO-d6): δ 51.75 (OCH3), 106.33, 110.29, 112.56, 112.63, 113.72, 
113.92, 114.63, 120.58, 123.10, 124.34, 136.63, 142.99, 159.12 (d, J = 247.0 Hz, C-6), 
42 
 
166.98 (C=O). Anal. Calcd for C14H10FNO3: C, 64.86; H, 3.89; N, 5.40%. Found: C, 64.82; 
H, 3.94; N, 5.35. 
4.16 Synthesis of methyl 1-(allyloxy)-9H-carbazole-3-carboxylate (20) 
 
To a stirred solution of 18 (0.19 g, 0.79 mmol) in dry acetone (10 mL) was added K2CO3 
(0.19 g, 1.34 mmol) and and the mixture was stirred for 20 min at room temperature. To 
the mixture was added NaI (0.12 g, 0.79 mmol) followed by the addition of allyl bromide 
(0.09 mL, 1.18 mmol) and the mixture was then stirred overnight at room temperature. 
After completion of the reaction (TLC analysis), the solvent was evaporated under reduced 
pressure. The residues were dissolved in ethyl acetate (20 mL) and successively washed 
with water (10 mL) and brine (10 mL). The organic layer was dried over anhydrous Na2SO4 
and concentrated under reduced pressure. The crude product was purified by column 
chromatography (20% ethyl acetate in hexanes) to furnish 20 as a yellow solid. Yield 0.16 
g, 72%; m.p. 175-178 oC; IR (neat): 3363, 2940, 2849, 1685, 1626, 1605, 1580, 1503, 1452, 
1432, 1405, 1337, 1311, 1242, 1150, 1091, 1016 cm-1; 1H-NMR (500 MHz, CDCl3): δ 3.96 
(s, 3H), 4.78 (d, J = 5.2 Hz, 2H), 5.35 (d, J = 10.7 Hz, 1H), 5.48 (d, J = 17.2 Hz, 1H), 6.13-
6.19 (m, 1H),  7.27 (t, J = 6.7 Hz, 1H), 7.43-7.49 (m, 2H), 7.59 (s, 1H), 8.08 (d, J = 7.6 Hz, 
1H), 8.47 (s, 1H), 8.52 (br s, 1H); 13C-NMR (125.7 MHz, CDCl3): δ 52.04, 69.38, 107.84, 
111.23, 116.35, 118.41, 120.28, 120.75, 121.84, 123.75, 126.40, 132.84, 133.05, 139.51, 
145.97, 167.91.  
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4.17 Synthesis of methyl 1-(allyloxy)-6-fluoro-9H-carbazole-3-carboxylate (21) 
 
 
Following the same procedure for the synthesis of 20, the reaction of 19 (0.23 g, 0.88 
mmol) with allyl bromide (0.13 mL, 1.51 mmol) gave the crude 21, which was purified by 
column chromatography eluting with hexanes-ethyl acetate (5:1) to furnish 21 as an off 
white solid. Yield 0.23 g, 86%; m.p. 186-188 oC; IR (neat): 3318, 2945, 2920, 1681, 1609, 
1581, 1505, 1478, 1457, 1437, 1327, 1300, 1279, 1250, 1165, 1095, 1021 cm-1; 1H-NMR 
(500 MHz, CDCl3): δ 3.98 (s, 3H), 4.80 (d, J = 5.5 Hz, 2H), 5.37 (dd, J = 10.7, 1.2 Hz, 
1H), 5.39 (dd, J = 17.4, 1.5 Hz, 1H), 6.16 (m, 1H), 7.20 (td, J = 8.8, 2.4 Hz, 1H), 7.41 (dd, 
J = 8.5, 4.0 Hz, 1H), 7.60 (d, J =  Hz, 1H), 7.74 (dd, J = 8.8, 2.1 Hz, 1H), 8.42 (s/d, 1H), 
8.50 (br s, 1H); 13C-NMR (125.7 MHz, CDCl3): δ 52.08, 69.42, 106.33, 106.52, 108.11, 
111.82, 111.89, 114.24, 114.43, 116.46, 118.50, 121.93, 132.74, 134.11, 135.80, 144.09, 
167.73.  
4.18 Synthesis of methyl 2-allyl-1-hydroxy-9H-carbazole-3-carboxylate (22) 
 
In a microwave reaction vessel containing a solution of 20 (0.8 g, 2.84 mmol) in DMF (2 
ml) was bubble nitrogen through the solution for 1 min and the vessel was placed inside 
CEM Discover S-Class microwave synthesizer where it was exposed to microwaves at 
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180oC (260 W) for 2 h. After completion of the reaction, the mixture was diluted with ethyl 
acetate (20 mL) washed with water (5 mL) and then washed with brine (3 x 5 mL), dried 
over anhydrous Na2SO4, filtered and concentrated under vacuum. Column chromatography 
purifications of the yellow oily material, eluting with ethyl acetate-hexane (1:1) yielded 
compound 22 as pale solid. Yield 0.6 g, 75%; m.p. 135-138 oC; IR (neat): 3335, 3056, 
3028, 2983, 2942, 1709, 1658, 1606, 1495, 1422, 1356, 1306, 1273, 1095 cm-1; 1H-NMR 
(500 MHz, CDCl3): δ 3.94 (s, 3H), 4.02 (d, J = 5.8 Hz, 2H), 5.18 (d, J = 7 Hz, 1H), δ 5.20 
(d, J =  Hz, 1H),  5.69 (br s, 1H), 6.12-6.18 (m, 1H),  7.24-7.27 (m, 1H), 7.41-7.46 (m, 2H), 
8.04 (d, J = 7.6 Hz, 1H), 8.37 (s, 1H), 8.48 (br s, 1H); 13C-NMR (125.7 MHz, CDCl3): δ 
31.37, 51.96, 111.12, 115.37, 116.87, 119.96, 120.51, 121.76, 122.37, 122.50, 123.70, 
126.15, 132.24, 137.23, 139.82, 140.37, 168.96. 
4.19 Synthesis of methyl 2-allyl-6-fluoro-1-hydroxy-9H-carbazole-3-
carboxylate (23) 
 
Following the same procedure adopted for the synthesis of compound 22, the reaction of 
21 (0.2 g, 0.66 mmol) in DMF (2 ml) in CEM Discover S-Class microwave synthesizer 
gave the product as a yellow oily material which was resolved on column chromatography, 
eluting with hexane-ethyl acetate (1:1) to afford compound 23 as a white solid. Yield 0.18 
g, 90%; m.p .125-130 oC; IR (neat): 3383, 2922, 2851, 2155, 1996, 1843, 1708, 1661, 1609, 
1494, 1453, 1433, 1347, 1288, 1253, 1220, 1166, 1031 cm-1; 1H-NMR (500 MHz, DMSO-
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d6): δ 3.80 (s, 3H), 3.89 (d, J = 5.8 Hz, 2H), 4.88-4.92 (m, 2H), 5.92 (m, 1H), 7.23 (td, J = 
8.8, 2.1 Hz, 1H), 7.53 (dd, J = 8.5, 4.3 Hz, 1H), 7.95 (dd, J = 9.7, 2.1 Hz, 1H), 8.22 (s, 1H), 
9.20 (br s, 1H), 11.09 (s, 1H); 13C-NMR (125.7 MHz, DMSO-d6): δ 29.87, 51.65, 105.93, 
106.12, 112.53, 113.43, 113.63, 120.83, 121.54, 123.76, 134.08, 136.42, 137.61, 140.34, 
168.16. 
4.20 Synthesis of methyl 2-allyl-1-methoxy-9H-carbazole-3-carboxylate (24) 
 
To a solution of 22 (0.25 g, 0.89 mmol) in DMF (5 mL) was added K2CO3 (0.15 g, 1.07 
mmol) and after being stirred at room temperature for 30 min, CH3I (0.07 mL, 1.07 mmol) 
was added to the mixture. The reaction was for 1 h at room temperature for 1 h and then 
diluted with water (30 mL) and extracted with ethyl ether (15 mL). The organic layer was 
successively washed with water (10 mL), brine (10 mL), dried over anhydrous Na2SO4, 
and evaporated under reduced pressure. Column chromatography of the light yellow 
material on silica gel eluting with ethyl acetate-hexanes (1:12) afforded 24 as white 
powder. Yield 0.19g, 73%; m.p. 98-100 oC; IR (neat): 3319, 2933, 2838, 2334, 1680, 1626, 
1604, 1494, 1450, 1428, 1387, 1341, 1251, 1221, 1137, 1095, 1040 cm-1; 1H-NMR (500 
MHz, CDCl3): δ 3.95 (s, 3H), 3.98 (s, 3H), δ 4.09 (d, J = 5.4 Hz, 2H), δ 5.00-5.06 (m, 2H), 
6.15-6.20 (m, 1H),  7.27 (t, J = 6.4 Hz, 1H), 7.42-7.45 (m, 2H), 8.07 (d, J = 7.9 Hz, 1H), 
8.58 (s, 1H), 8.81 (br s, 1H); 13C-NMR (125.7 MHz, CDCl3): δ 30.67, 51.94, 61.32, 111.18, 
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114.61, 120.22, 120.34, 120.46, 122.05, 122.90, 123.77, 126.37, 131.01, 135.55, 138.28, 
139.94, 143.35, 168.59. 
4.21 Synthesis of methyl 2-allyl-6-fluoro-1-methoxy-9H-carbazole-3-
carboxylate (25) 
 
Following the same procedure adopted for the synthesis of compound 24, the reaction of 
compound 23 (0.2 g, 0.66 mmol) with CH3I (0.05 mL, 0.8 mmol) gave, after the work up, 
the crude product which was purified by column chromatography on silica gel with ethyl 
acetate-hexanes (1:12) to yield 25 as a white solid. Yield: 0.15 g, 71%; m.p. 130-132 oC; 
IR (neat): 3341, 3066, 2936, 2828, 1677, 1630, 1607, 1495, 1461, 1438, 1386, 1326, 1281, 
1233, 1190, 1166, 1043, cm-1; 1H-NMR (500 MHz, CDCL3): δ 3.93 (s, 3H), 3.97 (s, 3H), 
4.02 (d, J = 5.8 Hz, 2H), 4.96 (dd, J = 17.1, 1.5 Hz, 1H), 5.01 (dd, J = 10.5, 1.5 Hz, 1H),  
6.11 (m, 1H), 7.19 (td, J = 8.8, 2.1 Hz, 1H), 7.41 (dd, J = 8.5, 4.0 Hz, 1H), 7.72 (dd, J = 
8.8, 2.1 Hz, 1H), 8.28 (br s, 1H), 8.46 (s, 1H); 13C-NMR (125.7 MHz, CDCl3): δ 30.66, 
51.95, 61.44, 106.28, 106.47, 111.71, 111.76, 114.17, 114.38, 114.69, 120.49, 122.52, 
122.59, 124.65, 131.72, 136.08, 136.56, 138.09, 143.53, 168.15. 
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4.22 Synthesis of Methyl 1-methoxy-2-(3-methylbut-2-en-1-yl)-9H-carbazole-3-
carboxylate (26) 
 
To a solution of compound 24 (0.19 g,  0.64 mmol) in anhydrous dichloromethane 
(20 ml) was added successively 2-methyl-2-butene (3.5 ml) and Grubbs’ second generation 
catalyst (0.016 g, 0.02 mmol) under nitrogen atmosphere. The solution was stirred for 24 
h at room temperature and concentrated under vacuum. Column chromatography of the 
dark brown oily material, eluting with ethyl acetate-hexane (1:6) gave compound 26 as 
colorless crystalline solid. Yield: 0.19 g, 91%; m.p. 129-133 oC; IR (neat): 3334, 2936, 
1707, 1685, 1626, 1605, 1568, 1494, 1430, 1389, 1342, 1242, 1097 cm-1; 1H-NMR (500 
MHz, CDCl3): δ 1.69 (s, 3H, CH3), 1.82 (s, 3H, CH3), 3.91-3.96 (m, 8H, 2 x OCH3, ArCH2-
), 5.24 (m, 1H, ArCH2CH=C(CH3)2), 7.25 (m, 1H, Ar-H), 7.42-7.45 (m, 2H, Ar-H), 8.07 
(d, J = 7.9 Hz, 1H, Ar-H), 8.58 (br. s, 1H, NH), 8.46 (s, 1H, Ar-H); 13C-NMR (125.7 MHz, 
CDCl3): δ 18.10 (CH3), 25.74 (CH3), 25.96 (CH2), 51.96 (OCH3), 61.08 (OCH3), 111.12, 
120.16, 120.20, 120.46, 122.37, 122.66, 123.91, 124.19, 126.28, 131.28, 133.21, 135.57, 
139.95, 143.22, 168.80 (C=O). Anal. Calcd for C20H21NO3: C, 74.28; H, 6.55; N, 4.33%. 
Found: C, 74.23; H, 6.60; N, 4.27. 
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4.23 Synthesis of Methyl 6-fluoro-1-methoxy-2-(3-methylbut-2-en-1-yl)-9H-
carbazole-3-carboxylate (27) 
 
Following the same procedure adopted for the synthesis of 26, the title compound 
27 was obtained as a white solid. Yield: 0.15 g, 84%; m.p. 115-116 oC; IR (neat): 3395, 
2967, 1692, 1631, 1609, 1587, 1485, 1434, 1377, 1345, 1320, 1274, 1230, 1187, 1167, 
1040 cm-1; 1H-NMR (500 MHz, CDCl3): δ 1.69 (s, 3H, CH3), 1.82 (s, 3H, CH3), 3.91-3.96 
(m, 8H, 2 x OCH3, ArCH2-), 5.22 (m, 1H, ArCH2CH=C(CH3)2), 7.17 (td, J = 2.4, 8.8 Hz, 
1H, Ar-H), 7.37 (dd, J = 4.2, 8.8 Hz, 1H, Ar-H), 7.68 (dd, J = 2.4, 8.8 Hz, 1H, Ar-H), 8.25 
(br. s, 1H, NH), 8.40 (s, 1H, Ar-H); 13C-NMR (125.7 MHz, CDCl3): δ 18.12 (CH3), 25.77 
(CH3), 25.94 (CH2), 52.00 (OCH3), 61.17 (OCH3), 106.35 (d, J = 24.9), 111.66 (d, J = 9.3), 
114.13 (d, J = 24.9), 120.33, 122.28, 122.68, 123.93, 124.61, 124.68, 131.52, 133.81, 
136.07, 136.55, 143.29, 157.89 (d, J = 236.5, C-6), 168.47 (C=O). Anal. Calcd for 
C20H20FNO3: C, 70.37; H, 5.91; N, 4.10%. Found: C, 70.33; H, 5.95; N, 4.06. 
4.24 Synthesis of 1-Methoxy-2-(3-methylbut-2-en-1-yl)-9H-carbazole-3-
carboxylic acid (28) 
 
To a solution of 26 (0.01 g, 0.30 mmol) in a mixture of MeOH (2 mL) and THF (1 
mL) was added a solution of KOH (15 mL, 30% in H2O) and the mixture was heated 
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overnight at 50 ºC. The reaction was cooled to room temperature, acidified to pH 4 with 
2M HCl and then extracted with ethyl acetate (2 x 30 mL). The organic layer was dried 
over anhydrous Na2SO4 and evaporated under reduced pressure. The residue was passed 
through a pad of silica, eluting with hexanes-ethyl acetate (1:1) to afford compound 28 as 
a white crystalline solid. Yield: 80%, m.p. 176-177 ºC; IR (neat): 3337, 3062, 2925, 1675, 
1610, 1448, 1406, 1278, 1236, 1031 cm-1; 1H-NMR (500 MHz, CD3OD): δ 1.57 (s, 3H, 
CH3), 1.72 (s, 3H, CH3), 3.83 (s, 3H, OCH3), 3.85 (d, J = 5.5 Hz, 1H, ArCH2-), 5.14 (m, 
1H, ArCH2CH=C(CH3)2), 7.08 (td, J = 1.1, 7.9 Hz, 1H, Ar-H), 7.28 (td, J = 1.2, 7.3 Hz, 
1H, Ar-H),  7.39 (d, J = 7.9 Hz, 1H, Ar-H), 7.93 (d, J = 7.9 Hz, 1H, Ar-H), 8.37 (s, 1H, 
Ar-H); 13C-NMR (125.7 MHz, CD3OD): δ 18.20 (CH3), 25.94 (CH3), 26.65 (CH2), 61.35 
(OCH3), 120.62, 120.95, 121.00, 123.13, 123.73, 124.79, 125.65, 127.08, 131.50, 133.87, 
137.05, 142.10, 144.72, 172.09 (C=O). Anal. Calcd for C19H19NO3: C, 73.77; H, 6.19; N, 
4.53%. Found: C, 73.72; H, 6.24; N, 4.48. 
4.25 Synthesis of 6-Fluoro-1-methoxy-2-(3-methylbut-2-en-1-yl)-9H-
carbazole-3-carboxylic acid (29) 
 
Following the same procedure adopted for the synthesis of 28, the basic hydrolysis 
of 27 gave the title compound 29 as a white crystalline solid from. Yield: 0.084 g, 77%; 
m.p. 196-197 ºC; IR (neat): 3455, 3040, 2913, 1664, 1634, 1612, 1588, 1569, 1489, 1443, 
1376, 1342, 1317, 1277, 1243, 1192, 1170, 1098 cm-1; 1H-NMR (500 MHz, CD3OD): δ 
1.65 (s, 3H, CH3), 1.79 (s, 3H, CH3), 3.91-3.96 (s, 5H, OCH3, ArCH2-), 5.22 (m, 1H, 
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ArCH2CH=C(CH3)2), 7.14 (td, J = 2.4, 8.8 Hz, 1H, Ar-H), 7.43 (dd, J = 4.3, 8.8 Hz, 1H, 
Ar-H), 7.70 (dd, J = 2.4, 8.8 Hz, 1H, Ar-H), 8.45 (s, 1H, Ar-H); 13C-NMR (125.7 MHz, 
CD3OD): δ 18.19 (CH3), 25.92 (CH3), 26.66 (CH2), 61.35 (OCH3), 106.53 (d, J = 23.86), 
113.05 (d, J = 9.34), 114.64 (d, J = 25.93), 121.28, 123.29, 125.34, 125.42, 125.79, 131.63, 
134.35, 138.10, 138.41, 144.79, 158.96 (d, J = 234.47, C-6), 171.92 (C=O). Anal. Calcd 
for C19H18FNO3: C, 69.71; H, 5.54; N, 4.28%. Found: C, 69.67; H, 5.58; N, 4.22. 
4.26 Synthesis of 3-(2-Hydroxypropan-2-yl)-5-methoxy-3,4-dihydropyrano[4,3-
b]carbazol-1(6H)-one (1) 
 
To an ice-cold solution of 28 (0.03 g, 0.08 mmol) in anhydrous CH2Cl2 (5 mL) was 
added m-CPBA (0.02 g, 0.12 mmol) and the reaction was stirred for 2 h at room 
temperature. After the completion of reaction (TLC analysis) the solvent was evaporated 
under vacuum and residue was diluted with H2O (5 mL) and extracted with ethyl acetate 
(2 x 10 mL). The combined organic extracts were washed with saturated NaHCO3 solution 
(2 x 6 mL) followed by water (6 mL) and brine (6 mL). The organic phase was dried over 
Na2SO4 and evaporated under vacuum. The residue was purified by silica column, eluting 
with hexanes-ethyl acetate (1:1) to get the title compound 1 as a light brown solid. Yield: 
0.02 g, 78%. All the spectral data of 1 matched with those of natural mafaicheenamine A 
[12]. 
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4.27 Synthesis of 9-Fluoro-3-(2-hydroxypropan-2-yl)-5-methoxy-3,4-
dihydropyrano[4,3-b]carbazol-1(6H)-one (2) 
 
Following the same procedure adopted for the synthesis of 1, the oxidative 
cyclization of 29 gave the title compound 2 as a white crystalline solid from. Yield: 0.036 
g, 80%; m.p. 276-277 ºC; IR (neat): 3506, 3218, 2989, 2971, 2933, 1691, 1634, 1612, 1584, 
1506, 1482, 1385, 1362, 1323, 1293, 1265, 1240, 1216, 1166, 1121, 1080, 1045 cm-1; 1H-
NMR (500 MHz, CD3OD): δ 1.38 (s, 3H, CH3), 1.39 (s, 3H, CH3), 3.00 (dd, J = 12.8, 16.4 
Hz, 1H, H-1'b), 3.45 (dd, J = 16.4, 2.7 Hz, 1H, H-1'a),  3.98 (s, 3H, OCH3), 4.29 (dd, J = 
2.7, 12.8 Hz, 1H, H-2'), 7.20 (dd, J = 6.4, 8.8 Hz, 1H, Ar-H), 7.48 (dd, J = 4.3, 8.8 Hz, 1H, 
Ar-H), 7.80 (dd, J = 2.4, 8.8 Hz, 1H, Ar-H), 8.55 (s, 1H, Ar-H); 13C-NMR (125.7 MHz, 
CD3OD): δ 21.96 (C-1'), 23.69 (CH3), 24.94 (CH3), 59.99 (OCH3), 70.41 (C-3'), 84.53 (C-
2'), 105.55 (d, J = 24.9), 111.94 (d, J = 9.3), 113.98 (d, J = 26.0), 115.65, 119.32, 123.66, 
123.86 (d, J = 9.3), 123.89, 128.53, 137.06, 137.84,  141.09, 157.79 (d, J = 235.5, C-6), 
167.49 (C=O). Anal. Calcd for C19H18FNO4: C, 66.46; H, 5.28; N, 4.08%. Found: C, 66.40; 
H, 5.33; N, 4.03. 
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4.28  (S)-methyl 2-acetamido-3-(3-allyl-4-hydroxyphenyl)propanoate (34) 
 
To a microwave reaction vessel containing a solution of aryl ether 33 (0.75 g, 2.70 
mmol) in N,N-dimethylaniline (4 ml). After gentle bubbling nitrogen through the solution 
for 1 min, the vessel was placed inside CEM Discover S-Class microwave synthesizer 
where it was exposed to microwaves at 250 oC (260 W) for 2 h. After completion of the 
reaction, the mixture was diluted with ethyl acetate (50 mL) and extracted with 3M 
hydrochloric acid (3 x 10 mL). The organic layer was washed successively with saturated 
sodium hydrogen carbonate (15 mL) and then brine (10 mL), dried over anhydrous sodium 
sulfate, filtered and concentrated under vacuum. Column chromatography purifications of 
the yellow oily material, eluting with ethyl acetate-hexane (1:1) yielded compound 34 as a 
pale yellow solid. Yield: 0.56 g, 75%; m.p. 91-92 oC; [α]D25 +25.95 (c. 1.15, CHCl3); IR 
(neat): 3418, 3300, 3081, 3006, 2956, 1717, 1662, 1510, 1432, 1209, 1121 cm-1; 1H-NMR 
(CDCl3, 500 MHz): δ 1.92 (s, 3H, NCOCH3), 2.96 (dd, 2H), 3.27 (m, 2H), 3.66 (s, 3H, 
OCH3), 4.76 (m, 1H), 4.99-5.03 (m, 2H), 5.90 (m, 1H), 5.99 (d, 1H, J = 7.9 Hz, NH), 6.62 
(m, 1H, aromatics), 6.72 (m, 2H, aromatics); 13C-NMR (CDCl3, 500 MHz): δ 23.05, 34.46, 
37.05, 52.35, 53.31, 115.64, 116.07, 125.92, 127.26, 128.13, 131.04, 136.46, 153.39, 
170.05, 172.29. Anal. calcd. for C15H19NO4: C, 64.97; H, 6.91; N, 5.05. Found: C, 64.93; 
H, 6.94; N, 5.01.  
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4.29 (S)-methyl 2-acetamido-3-(4-acetoxy-3-allylphenyl)propanoate (35) 
 
To a solution of compound 34 (0.5 g, 1.80 mmol) in anhydrous dichloromethane 
(15 mL) at 0 oC was added triethylamine (0.75 ml, 5.41 mmol). After bring stirred for 10 
minutes, acetic anhydride (0.35 ml, 3.60 mmol) was added dropwise and the reaction was 
stirred for 2 h at room temperature. The mixture was added ethyl acetate (30 mL) and 
washed successively with saturated sodium hydrogen carbonate (15 mL) and brine (10 
mL). The organic layer was dried over anhydrous sodium sulfate and evaporated under 
vacuum to obtain compound 35 as an off-white solid. Yield: 0.57 g, 99%; m.p. 104 oC; 
[α]D25 +56.6 (c. 1.0, CHCl3); IR (neat): 3311, 3086, 2948, 1740, 1649, 1639, 1543, 1497, 
1433, 1371, 1202, 1185, 1166 cm-1; 1H-NMR (CDCl3, 500 MHz): δ 1.99 (s, 3H, NCOCH3), 
2.29 (s, 3H, COCH3), 3.10 (t, 2H, J = 5.5 Hz), 3.25 (d, 2H, J = 6.7 Hz), 3.72 (s, 3H, OCH3), 
4.86 (m, 1H), 5.03-5.09 (m, 2H), 5.85 (m, 1H), 5.89 (d, 1H, J = 7.9 Hz, NH), 6.96 (m, 3H, 
aromatics); 13C-NMR (CDCl3, 500 MHz): δ 23.18, 29.71, 34.45, 37.16, 52.38, 53.06, 
116.47, 122.47, 128.18, 131.23, 132.03, 133.70, 135.70, 148.01, 169.35, 169.61, 171.94. 
Anal. calcd. for C17H21NO5: C, 63.94; H, 6.63; N, 4.39. Found: C, 63.90; H, 6.68; N, 4.32. 
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4.30 (S)-methyl 2-acetamido-3-(4-acetoxy-3-(3-methylbut-2-en-1-
yl)phenyl)propanoate (36) 
 
To a solution of compound 35 (0.23 g,  0.72 mmol) in anhydrous dichloromethane 
(36 ml) was added successively 2-methyl-2-butene (4 ml) and Grubbs’ second generation 
catalyst (0.018 g, 0.021 mmol) under nitrogen atmosphere. The solution was stirred for 24 
h at room temperature and concentrated under vacuum. Column chromatography of the 
dark brown oily material, eluting with ethyl acetate:hexane (2:3) gave compound 36 as a 
light yellow solid (0.21 g, 84%). Yield: 0.21 g, 84%; m.p. 81-82 oC; [α]D25 -59.7 (c. 0.22, 
CHCl3). IR (neat): 3288, 3061, 2951, 1735, 1649, 1539, 1492, 1370, 1185, 1164 cm
-1; 1H-
NMR (CDCl3, 500 MHz): δ 1.69 (s, 3H), 1.74 (s, 3H), 1.99 (s, 3H, NCOCH3), 2.30 (s, 3H, 
COCH3), 3.10 (m, 2H), 3.25 (d, 2H, J = 7.3 Hz), 3.72 (s, 3H, OCH3), 4.87 (m, 1H), 5.29 
(m, 1H), 5.92 (d, 1H, J = 9.7 Hz, NH), 6.93 (m, 3H, aromatics); 13C-NMR (CDCl3, 500 
MHz): δ 17.82, 23.14, 25.77, 28.59, 29.71, 37.15, 52.31, 53.03, 121.38, 122.31, 127.76, 
130.83, 133.41, 133.61, 147.96, 169.41, 169.59, 171.96. Anal. calcd. for C19H25NO5: C, 
65.69; H, 7.25; N, 4.03. Found: C, 65.63; H, 7.30; N, 3.97.  
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4.31 (S)-2-acetamido-3-(4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl)propanoic acid 
(3) 
 
To a solution of compound 8 (0.16 g, 0.46 mmol) in a mixture of tetrahydrofuran, 
methanol and water (10 ml, in 3:1:1 ratio) was added lithium hydroxide monohydrate 
(0.096 g, 2.3 mmol) and the mixture was stirred for 3 h at room temperature. The solvent 
was evaporated and residue was diluted with chloroform (20 ml) and washed with 1M 
hydrochloric acid (3 ml). The organic layer was dried over anhydrous Na2SO4, 
concentrated under vacuum and passed over a plug of silica, eluting with methanol-
dichloromethane (0.5:9.5) to afford compound 1 as a colorless solid (0.09 g, 69%). The 
spectral data of 1 coincided with literature values [12]. 
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CHAPTER 5   
CONCLUSION AND RECOMMENDATIONS 
 
 The first total synthesis of tyrosine derivative 3 for its antitumoral activity was 
successfully achieved in overall high yielding sequence. The first total synthesis of 
anticancer natural product mafaicheenamine A 1 was accomplished. Substitution of 
aromatic and heteroaromatic rings with fluorine substituent is a common practice in drug 
discovery resulting in enhanced drug potency, target selectivity and drug metabolism. 
Therefore the fluoro analogue of 1 was synthesized. Our synthetic strategy also has led to 
the expedient route to realize an important naturally anticancer product clausine-E that is a 
common intermediate in the synthesis of other naturally occurring bioactive carbazole 
alkaloids. Our approach paved a way to synthesize clausine-E in overall yield of 34% from 
commercially available methyl 4-amino-3-(benzyloxy)benzoate (18). Similarly, the 
unnatural 6-Fluoro analogue of clausine was afforded from our synthetic sequence. The 
unnatural 6-Fluoromafaicheenamine A 2 and 6-Fluoroclausine can be screened for its 
potential pharmacological activities. 
 
 
 
 
 
 
57 
 
References 
1. Mohan, K. & Jeyachandran, R. Alkaloids as anticancer agents. Ann. phytomedicine 1, 
46–53, 2012. 
2. Bhanot, A., Sharma, R. & Noolvi, M. N. Natural sources as potential anti-cancer 
agents: A review. Int. J. Phytomedicine 3, 09–26, 2011. 
3. Yokota, J. Tumor progression and metastasis. Carcinogenesis 21, 497–503, 2000. 
4. DeVita, V. T. & Chu, E. A history of cancer chemotherapy. Cancer Res. 68, 8643–
8653, 2008. 
5. Prakash, O., Kumar, A., Kumar, P. & Ajeet, A. Anticancer Potential of Plants and 
Natural Products: A Review. Am. J. Pharmacol. Sci. 1, 104–115, 2013. 
6. Alison, M. R. Cancer. Encyclopedia of Life Sciences 1–8, 2001.  
7. Wong, R. S. Y. Apoptosis in cancer: from pathogenesis to treatment. J. Exp. Clin. 
Cancer Res. 30, 87, 2011. 
8. Reed, J. C. Drug insight: cancer therapy strategies based on restoration of endogenous 
cell death mechanisms. Nat. Clin. Pract. Oncol. 3, 388–98, 2006. 
9. Pitti, R. M.; Marsters, S. A.; Ruppert, S.; Donahue, C. J.; Moore, A.; Ashkenazi, A. J. 
Biol. Chem. 271, 12687-12690, 1996. 
10. Wiley, S. R.; Schooley, K.; Smolak, P. J.; Din, W. S.; Huang, C-P.; Nicholl, J. K.; 
Sutherland, G. R.; Smith, T. D.; Rauch, C.; Smith, C. A.; Goodwin, R. G. Immunity, 3, 
673-682, 1995. 
58 
 
11. Ashkenazi, A. Nat. Rev. Cancer, 2, 420-430, 2002. 
12. Pan, G.; Ni, J.; Wei, Y. F.; Yu, G.; Gentz, R.; Dixit, V. M. Science, 277, 815-818, 1997. 
13. Schneider, P.; Thome, M.; Burns, K.; Bodmer, J. L.; Hofmann, K.; Kataoka, T.; Holler, 
N.; Tschopp, J. Immunity, 7, 831-836, 1997. 
14. Chaudhary, P. M.; Eby, M.; Jasmin, A.; Bookwalter, A.; Murray, J.; Hood, L. 
Immunity, 7, 821-830, 1997. 
15. Wu, G. S.; Burns, T. F.; McDonald, E. R 3rd.; Jiang, W.; Meng, R.; Krantz, I. D.; Kao, 
G.; Gan, D. D.; Zhou, J. Y.; Muschel, R.; Hamilton, S. R.; Spinner, N. B.; Markowitz, 
S.; Wu, G.; el-Deiry, W. S. Nat. Genet., 17, 141-143, 1997. 
16. Ashkenazi, A.; Dixit, V. M. Curr. Opin. Cell. Biol. 11, 255-260, 1999. 
17. Ishibashi, M.; Ohtsuki, T. Med. Res. Rev., 28, 688-714, 2008. 
18. Ahmed, F.; Toume, K.; Sadhu, S. K.; Ohtsuki, T.; Arai, M. A.; Ishibashi, M. Org. 
Biomol. Chem., 8, 3696–3703, 2010.  
19. Zhang, L.; Fang, B. Cancer Gene Ther., 12, 228-237, 2005. 
20. Butler, M. S. The role of natural product chemistry in drug discovery. J. Nat. Prod. 67, 
2141–2153, 2004. 
21. Dioscorides in De materia medica; Wellmann, M., Ed.; Weidmann: Berlin, 1906-1914 
22. Pelletier, P. S.; Cavention, J. J. Ann. Chim. Phys., 14, 69, 1820. 
23. Lavie, D.; Willner, D. J. Am. Chem. Soc. 80, 710-714, 1958. 
24. Noble, R. L.; Beer, C. Ann. NY Acad. Sci., 76, 882, 1958. 
59 
 
25. Gueritte, F.; Fahy, J. in The vinca alkaloids; Cragg, G. M., Kingston, D. G. I. and 
Newman, D. J., Eds.; Anticancer agents from natural products; Taylor and Francis: 
Boca Raton,; pp 123-136, 2005. 
26. Duflos A.; Kruczynski A.; Barret J-M. Curr. Med. Chem.: Anti-Cancer Agents, 2, 55-
70, 2002. 
27. Cragg, G.; Newman, D. Phytochem. Rev., 8, 313-331, 2009 
28. Burnett, A. R.; Thomson, R. H. J. Chem. Soc. C: Organic, 21, 2100-2104, 1967. 
29. Pettit, G. R.; Cragg, G. M.; Herald, D. L.; Schmidt, J. M.; Lohavanijaya, P. Can. J. 
Chem., 60, 1374-1376, 1982. 
30. Kingston, D. G. I. In Taxol and its analogues; Cragg, G. M., Kingston, D. G. I. and 
Newman, D. J., Eds.; Anticancer agents from natural products; Taylor and Francis: 
Boca Raton,; pp 89-122, 2005. 
31. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. J. Am. Chem. Soc. 
93, 2325-2327, 1971. 
32. Oberlies, N. H.; Kroll, D. J. J. Nat. Prod. 67, 129-135, 2004. 
33. Gueritte-Voegelein, F.; Guenard, D.; Lavelle, F.; Le Goff, M. T.; Mangatal, L.; Potier, 
P. J. Med. Chem., 34, 992-998, 1991. 
34. da Rocha, A. Natural products in anticancer therapy. Curr. Opin. Pharmacol. 1, 364–
369, 2001. 
60 
 
35. Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the 30 
years from 1981 to 2010. J. Nat. Prod. 75, 311–335, 2012. 
36. a. Kongkathip, N., Kongkathip, B. Heterocycles, 79, 121, 2009. b. Rahman, M.M., 
Gray, A.I. Phytochemistry, 66, 1601, 2005.  
37. Wang, J., Zheng, Y., Efferth, T., Wang, R., Shen, Y., Hao, X. Phytochemistry, 66, 697, 
2005. 
38. Delamare, A.P.L., Pistorello, I.T.M., Artico, L., Serafini, L.A., Echeverrigaray, S. 
Food Chem., 100, 603–608, 2007. 
39. Jagadeesh, S., Sinha, S., Pal, B.C., Bhattacharya, S., Banerjee, P.P. Biochem. Biophys. 
Res. Commun., 362, 212–217, 2007. 
40. Sathaye, S., Bagal, Y., Gupta, S., Kaur, H., Redkar, R. Exp. Toxicol. Pathol., 63, 587–
591, 2011. 
41. Cordell, G.A. The Alkaloids: Chemistry and Biology; Academic Press: Waltham, MA, 
USA, 65, 1–430, 2008. 
42. Sakano, K., Ishimaru, K., Nakamura, S. J. Antibiot., 33, 683-689, 1980. 
43. Knölker, H., Fröhner, W. J. Chem. Soc., Perkin Tran. I, 173-175, 1998. 
44. Itoigawa M., Kashiwada, Y., Ito, C., Furukawa, H., Tachibana, Y., Bastow, K. F., Lee, 
K. J. Nat. Prod., 63, 893-897, 2000. 
45. Cui, C., Yan, S., Cai, B., Yan, X. J. Asian Nat. Prod. Res., 4(4), 233-241, 2002. 
61 
 
46. (a) Le Pecq, J. B., Pat-Xuong, N., Gosse, C., Paolett, C. Proc. Nat. Acad. Sci., U. S. A., 
71, 5078, 1974 (b) Stiborova, M., Breuer, A., Almova, D., Stiborova-Rupertova, M., 
Wiessler, M., Frei, E. Int. J. Cancer,  107, 885-890, 2003. 
47. Wang, Y., He, H., Shen, Y., Hong, X., Hao, X. J. Nat. Prod., 66, 416-418, 2003. 
48. Kim, M. Y., Lim, J. I., Kim, D. S., Kim, I. Y., Yang, J. S. Heterocycles, 45, 2041, 1997. 
49. (a) Lin, G., Zhang, A. Tetrahedron, 56, 7163-7171, 2000. (b) Itoigawa, M., Kashiwada, 
Y., Ito, C., Furukawa, H., Tachibana, Y., Bastow, K. F., Lee, K. J. Nat. Prod., 63, 893-
897, 2000. 
50.  Ito, C., Wu, T. S., Furukawa, H. Chem. Pharm. Bull., 38, 1143-1146, 1990. 
51. Maneerat, W., Laphookhieo, S. Heterocycles, 81(5), 1261-1268, 2010. 
52. Ito, C. et al. Induction of apoptosis by carbazole alkaloids isolated from Murraya 
koenigii. Phytomedicine 13, 359–365, 2006. 
53. Peh, T. H., Lim, G. K., Taufiq-yap, Y. H., Cheng, G. & Ee, L. A New Cytotoxic 
Carbazole Alkaloid Isolated from the Stem Bark of Malaysian Clausena excavata. 1, 
165–172, 2013. 
54. Nakahara, K. et al. Antimutagenicity of some edible Thai plants, and a bioactive 
carbazole alkaloid, mahanine, isolated from Micromelum minutum. J. Agric. Food 
Chem. 50, 4796–4802, 2002. 
55. Ito, C. et al. New carbazole alkaloids from Clausena anisata with antitumor promoting 
activity. J. Nat. Prod. 63, 125–128, 2000. 
62 
 
56. Du, Y. Q. et al. Bioactive carbazole alkaloids from the stems of Clausena lansium. 
Fitoterapia 103, 122–128, 2015. 
57. Bergman, J. & Pelcman, B. Synthesis of carbazole alkaloids. Pure Appl. Chem. 62, 
1967–1976, 1990. 
58. Y. Oikawa, O. Yonemiuu, Heterocycles, 5,233, 1976. 
59.  Knölker, H.-J.; Budei, F.; Pannek, J.-B.; Schlechtingen, G.Synlett, 587, 1996. 
60. a) Kno¨lker, H.-J. In Transition Metals for Organic Synthesis; Beller, M., Bolm, C.,      
Eds.; Wiley-VCH: Weinheim,; 1, Chapter 3.13, p 534, 1998. (b) Kno¨lker, H.-J. Chem. 
Soc. Rev., 28, 151, 1999. 
61. Liebeskind, L. S.; McCallum, J. S. Organometallics, 12, 927, 1993. 
62. Naykode, M. S., Humne, V. T. & Lokhande, P. D. A one-pot direct iodination of the 
Fischer-Borsche ring using molecular iodine and its utility in the synthesis of 6-
oxygenated carbazole alkaloids. J. Org. Chem. 80, 2392–2396, 2015. 
63. Roy, J., Jana, A. K. & Mal, D. Recent trends in the synthesis of carbazoles: An update. 
Tetrahedron 68, 6099–6121, 2012. 
64. Zhang, A. & Lin, G. The first synthesis of clausenamine-A and cytotoxic activities of 
three biscarbazole analogues against cancer cells. Bioorganic Med. Chem. Lett. 10, 
1021–1023, 2000. 
65. Borger C, Knolker H-J, Synlett 1698–1702, 2008. 
63 
 
66. Sridharan V., Martin M. A., Menndez J.C., Eur J Org Chem 4614–4621, 2009. 
67. Akermark B., Eberson L., Jonsson E., Pettersson E., J Org Chem. 40,1365–1367, 1975. 
68. Knolker H-J, O’Sullivan N., Tetrahedron 50, 10893–10908, 1994. 
69. D. R. Vutukuri, P. Bharathi, Z. Yu, K. Rajasekaran, M.-H. Tran, S. Thayumanavan, J. 
Org. Chem., 68, 1146-1149, 2003. 
70. A. B. Gamble, J. Garner, C. P. Gordon, S. M. J. O'Conner, P. A. Keller, Synth. 
Commun., 37, 2777-2786, 2007. 
71. D. H. R. Barton, D. M. X. Donnelly, J.-P. Finet, P. J. Guiry, J. Chem. Soc. Perkin Trans. 
1, 2095-2102, 1991. 
72. H.-J., Knolker, N. O’Sullivan, Tetrahedron, 50, 10893-10908, 1994. 
73. M. Schmidt, H.-J. Knolker, Synlett, 15, 2421-2424, 2009. 
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